IDL Diagnostics AB (publ) (IDLDX.ST)
IDL Diagnostics AB (publ) operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Stockholm, SE. The stock last traded at $0.39, down 1.52% on the session, giving a market capitalisation of $89.4M. Its beta of 0.94 implies it has historically moved less than the broad market.
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
IDL Diagnostics AB (publ) is most often compared with the following Healthcare names: